Ali Omar Yassen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali Omar Yassen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Ansam Naji Alhassani
1 shared publication- Asmaa A. Haydar
Department of Pharmacology and Toxicology, College of Pharmacy, HMU, Erbil, Iraq
1 shared publication Asmaa Awni Haydar
1 shared publicationAya Diyar Bilal
Tishk Int Univ, Pharm Dept, Erbil 44001, Kurdistan, Iraq
1 shared publicationErbil Raparin Teaching Hospital
1 shared publication- Farhana Fakhira Ismail
Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) Cawangan Selangor, Kampus Puncak Alam, Puncak Alam 42300, Malaysia
1 shared publication
Latest Publications
- Open Access
- 12 August 2025
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 38 (3) , 133-138
Monitoring of patients with concomitant diseases post coronavirus infection
This survey study presents data on the prevalence of, and the risk factors associated with post-COVID-19 complications for surviving patients with concomitant diseases during and after months of infection by coronavirus. A prospective, questionnaire-based study was conducted from May 2021 to June 2022. Patients who recovered from COVID-19 in 62 countries completed the online survey or did so during visits to hospitals and health centers. Individuals who recovered from COVID-19 were asked about their symptoms, adverse effects and adverse drug reactions. They were also asked if their concomitant diseases (diabetes, cardiovascular illness, asthma and GIT diseases) were affected after infection and if they had an uncontrolled treatment regimen. The severity of COVID was studied and the correlation coefficient to uncontrolled concomitant diseases was analyzed. Overall, 844 patients (44% female, 56% male) were assessed, and the highest percentage were suffering from long-term cough, dyspnea, constipation and uncontrolled concomitant diseases. A high significantly positive correlation between the severity of COVID infection and uncontrolled concomitant diseases was recorded. Many patients with mild to severe disease presentation reported persistent symptoms months later. Long-term complications to the lungs, heart, vascular system, kidneys, as well as metabolic disruption appear as uncontrolled treatment regimens for surviving COVID-19 patients.
- 12 August 2025
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 38 (3) , 133-138
Open AccessMonitoring of patients with concomitant diseases post coronavirus infection
This survey study presents data on the prevalence of, and the risk factors associated with post-COVID-19 complications for surviving patients with concomitant diseases during and after months of infection by coronavirus. A prospective, questionnaire-based study was conducted from May 2021 to June 2022. Patients who recovered from COVID-19 in 62 countries completed the online survey or did so during visits to hospitals and health centers. Individuals who recovered from COVID-19 were asked about their symptoms, adverse effects and adverse drug reactions. They were also asked if their concomitant diseases (diabetes, cardiovascular illness, asthma and GIT diseases) were affected after infection and if they had an uncontrolled treatment regimen. The severity of COVID was studied and the correlation coefficient to uncontrolled concomitant diseases was analyzed. Overall, 844 patients (44% female, 56% male) were assessed, and the highest percentage were suffering from long-term cough, dyspnea, constipation and uncontrolled concomitant diseases. A high significantly positive correlation between the severity of COVID infection and uncontrolled concomitant diseases was recorded. Many patients with mild to severe disease presentation reported persistent symptoms months later. Long-term complications to the lungs, heart, vascular system, kidneys, as well as metabolic disruption appear as uncontrolled treatment regimens for surviving COVID-19 patients.
- Open Access
- 30 October 2024
- Published by Cihan University of Erbil in Cihan University-Erbil Scientific Journal
- Vol. 8 (2) , 104-109
A Comparative Study of Efficacy and Safety among Metformin, Sitagliptin, and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus
Effective management of type 2 diabetes mellitus (T2DM) requires lifestyle changes and suitable medications to enhance quality of life and prevent complications. Choosing the right treatment involves considering the patient's clinical profile, drug efficacy, side effects, and cost. This study compares the safety and efficacy of sitagliptin, glimepiride, and metformin in T2DM patients. A prospective cross-sectional study was conducted at the Diabetes Center of Layla Qasim, Erbil, Iraq, including 143 diabetic patients. They were divided into three groups: group A received glimepiride (N=50), group B metformin (N=48), and group C sitagliptin (N=45). Drug costs, therapeutic outcomes, and side effects were analyzed. Patients aged 30 to 78 participated, with a female-to-male ratio of 83:60. All groups showed significantly improved HbA1c levels (P=0.001). Total cholesterol (TC) and LDL levels were also significantly different (P=0.047 and P=0.010, respectively). Sitagliptin significantly increased triglycerides (TG) and HDL-C. Gastrointestinal side effects were prominent in the metformin group. When selecting medication for T2DM, factors like age, HbA1c, glucose levels, obesity, metabolic syndrome, insulin secretion, and hypoglycemia risk should be considered. Both sitagliptin and glimepiride were well tolerated, with minimal hypoglycemia risk and no significant weight differences between groups. Glimepiride is an effective, safe, and weight-neutral adjunct to metformin, offering extrapancreatic benefits and remains a viable second-line treatment option for T2DM patients.
- 30 October 2024
- Published by Cihan University of Erbil in Cihan University-Erbil Scientific Journal
- Vol. 8 (2) , 104-109
Open AccessA Comparative Study of Efficacy and Safety among Metformin, Sitagliptin, and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus
Effective management of type 2 diabetes mellitus (T2DM) requires lifestyle changes and suitable medications to enhance quality of life and prevent complications. Choosing the right treatment involves considering the patient's clinical profile, drug efficacy, side effects, and cost. This study compares the safety and efficacy of sitagliptin, glimepiride, and metformin in T2DM patients. A prospective cross-sectional study was conducted at the Diabetes Center of Layla Qasim, Erbil, Iraq, including 143 diabetic patients. They were divided into three groups: group A received glimepiride (N=50), group B metformin (N=48), and group C sitagliptin (N=45). Drug costs, therapeutic outcomes, and side effects were analyzed. Patients aged 30 to 78 participated, with a female-to-male ratio of 83:60. All groups showed significantly improved HbA1c levels (P=0.001). Total cholesterol (TC) and LDL levels were also significantly different (P=0.047 and P=0.010, respectively). Sitagliptin significantly increased triglycerides (TG) and HDL-C. Gastrointestinal side effects were prominent in the metformin group. When selecting medication for T2DM, factors like age, HbA1c, glucose levels, obesity, metabolic syndrome, insulin secretion, and hypoglycemia risk should be considered. Both sitagliptin and glimepiride were well tolerated, with minimal hypoglycemia risk and no significant weight differences between groups. Glimepiride is an effective, safe, and weight-neutral adjunct to metformin, offering extrapancreatic benefits and remains a viable second-line treatment option for T2DM patients.
- Open Access
- 29 May 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-10
Antidepressant adherence among outpatients with major depressive disorder
Major Depressive Disorder (MDD) is a global mental health concern, with treatment often involving antidepressant (AD) medications. However, adherence to these medications remains a significant challenge. This study aims to investigate the factors influencing medication adherence among individuals with MDD in Erbil, Iraq. This study was conducted at Erbil Psychiatric Hospital, a leading mental healthcare facility in Erbil city. Participants aged 18 to 65, diagnosed with MDD as per the DSM-5 criteria, were treated with antidepressants. The recruitment of 106 participants was facilitated by their treating psychiatrists at the hospital. Data analysis was conducted using SPSS version 22, standard for social science research. Out of the 106 participants, 64.2% were females, and 35.8% were males. The largest age group was 35–45, comprising 33% of the sample. A vast majority (99.1%) were under regular follow-up, with only 0.9% experiencing relapse. The primary antidepressant used was selective serotonin reuptake inhibitors (SSRIs) (72.6%). Most participants (61.3%) reported very high medication adherence. The notable barriers included treatment duration (13.4%), forgetting to take antidepressants (11.9%), frequent medication refills (17.9%), cultural and religious beliefs (19.3%), stigma (19.3%), travelling issues (42.9%), and lack of hospitals and clinics (30.8%). Healthcare facilitators such as effectiveness of antidepressants (27.5%), patient-provider relationship such as trusting healthcare providers (50.7%), and reminders such as keeping pills in visible places (65.9%) were prominent facilitators aiding adherence. Future research should focus on culturally tailored interventions and collaborative efforts among stakeholders. By addressing socio-cultural nuances and enhancing mental health support, more effective strategies can be developed to tackle medication adherence challenges in Erbil’s unique context.
- 29 May 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-10
Open AccessAntidepressant adherence among outpatients with major depressive disorder
Major Depressive Disorder (MDD) is a global mental health concern, with treatment often involving antidepressant (AD) medications. However, adherence to these medications remains a significant challenge. This study aims to investigate the factors influencing medication adherence among individuals with MDD in Erbil, Iraq. This study was conducted at Erbil Psychiatric Hospital, a leading mental healthcare facility in Erbil city. Participants aged 18 to 65, diagnosed with MDD as per the DSM-5 criteria, were treated with antidepressants. The recruitment of 106 participants was facilitated by their treating psychiatrists at the hospital. Data analysis was conducted using SPSS version 22, standard for social science research. Out of the 106 participants, 64.2% were females, and 35.8% were males. The largest age group was 35–45, comprising 33% of the sample. A vast majority (99.1%) were under regular follow-up, with only 0.9% experiencing relapse. The primary antidepressant used was selective serotonin reuptake inhibitors (SSRIs) (72.6%). Most participants (61.3%) reported very high medication adherence. The notable barriers included treatment duration (13.4%), forgetting to take antidepressants (11.9%), frequent medication refills (17.9%), cultural and religious beliefs (19.3%), stigma (19.3%), travelling issues (42.9%), and lack of hospitals and clinics (30.8%). Healthcare facilitators such as effectiveness of antidepressants (27.5%), patient-provider relationship such as trusting healthcare providers (50.7%), and reminders such as keeping pills in visible places (65.9%) were prominent facilitators aiding adherence. Future research should focus on culturally tailored interventions and collaborative efforts among stakeholders. By addressing socio-cultural nuances and enhancing mental health support, more effective strategies can be developed to tackle medication adherence challenges in Erbil’s unique context.
- Open Access
- 7 March 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 12-27
A REVIEW ON DEVELOPMENT OF COLON TARGETED DRUG DELIVERY SYSTEM
The purpose of this review was to select a promising drug delivery system for colon diseases. This review covers the development of Colon Targeted Drug Delivery System (CTDDS) using 36 y (1986-2022) data from various research and review articles. All fig. designed using by BioRender website. vThe colon-targeted drug delivery systems developed for the specific site drug delivery which applied for both local and systemic actions of the drug; since the drug targeted to be release within the colon, the unwanted systemic side effects are reduced along with it. Systemic side effects include organ damage, respiratory diseases and, cardiovascular damage and other illnesses. Colon-targeted drug delivery system used in the treatment of diseases in the colon, including ulcerative colitis, irritable bowel syndrome and colorectal cancer. The benefit of colon-targeted drug delivery besides the reduction of side effects also include protection from premature drug release or burst in the stomach or small intestine before reaching the colon. For the development of drugs with such benefits and advantages, drug delivery systems and approaches have used for Colon targeted drug delivery systems, varying from conventional colon-targeting drug delivery systems to novel approaches for Colon-targeted drug delivery systems. Conventional drug delivery includes the use of prodrugs, pH-dependent, time-dependent, matrix-based systems, polysaccharides-derived systems, and bio-adhesive system while novel approaches include types such as port system, pulsincap system, pressure-controlled system, osmotic controlled system, CODES, and the newest approach wish is the use of nanotechnology in colon targeted drug delivery. In this research both techniques reviewed, and their types discussed as well. The limitation of their uses and the advantage of each system discussed with a breakdown of the different mechanisms used to formulate such systems. A successful colon targeting delivery can release the drug to a specific segment in colon due to presence of different colonic enzymes formed by microorganisms that metabolize drug carrier linkage. Use of combined approaches i.e., conventional systems and newer approaches may be the best way to cure colon diseases using an optimized colon drug delivery system.
- 7 March 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 12-27
Open AccessA REVIEW ON DEVELOPMENT OF COLON TARGETED DRUG DELIVERY SYSTEM
The purpose of this review was to select a promising drug delivery system for colon diseases. This review covers the development of Colon Targeted Drug Delivery System (CTDDS) using 36 y (1986-2022) data from various research and review articles. All fig. designed using by BioRender website. vThe colon-targeted drug delivery systems developed for the specific site drug delivery which applied for both local and systemic actions of the drug; since the drug targeted to be release within the colon, the unwanted systemic side effects are reduced along with it. Systemic side effects include organ damage, respiratory diseases and, cardiovascular damage and other illnesses. Colon-targeted drug delivery system used in the treatment of diseases in the colon, including ulcerative colitis, irritable bowel syndrome and colorectal cancer. The benefit of colon-targeted drug delivery besides the reduction of side effects also include protection from premature drug release or burst in the stomach or small intestine before reaching the colon. For the development of drugs with such benefits and advantages, drug delivery systems and approaches have used for Colon targeted drug delivery systems, varying from conventional colon-targeting drug delivery systems to novel approaches for Colon-targeted drug delivery systems. Conventional drug delivery includes the use of prodrugs, pH-dependent, time-dependent, matrix-based systems, polysaccharides-derived systems, and bio-adhesive system while novel approaches include types such as port system, pulsincap system, pressure-controlled system, osmotic controlled system, CODES, and the newest approach wish is the use of nanotechnology in colon targeted drug delivery. In this research both techniques reviewed, and their types discussed as well. The limitation of their uses and the advantage of each system discussed with a breakdown of the different mechanisms used to formulate such systems. A successful colon targeting delivery can release the drug to a specific segment in colon due to presence of different colonic enzymes formed by microorganisms that metabolize drug carrier linkage. Use of combined approaches i.e., conventional systems and newer approaches may be the best way to cure colon diseases using an optimized colon drug delivery system.
- 1 January 2024
- Published by Cihan University of Erbil
- p. 505-509
Effect of Filgrastim in Febrile Neutropenia Patients Who Received Chemotherapy Regimens in The Community on Oncology Practice
—Background: Granulocyte colony-stimulating factors (G-CSFs) have been shown to help prevent febrile neutropenia in certain subgroups of cancer patients undergoing chemotherapy, but their role in treating febrile neutropenia is controversial. The purpose of our study was to evaluate—in a prospective multicenter randomized clinical trial—the efficacy of adding G-CSF to broad- spectrum antibiotic treatment of patients with solid tumors and high-risk febrile neutropenia. Patients and Methods: . This retrospective cohort study included seventy adult patients of both genders, aged 20 years and older, treated for cancer at Nanakali Hospital between October 2021 and January 2022. Data on filgrastim use and treatment outcomes were collected from electronic medical records. Results: Patients with 35 (50%) male and 35 (50%) female patients were assessed Based on observations from the administration series, (G-CSFs) use. Higher level acute myeloid leukemia (N=25) and lower one larynx carcinoma (N=1) were the most common malignancies, both of which were treated with (G-CSFs) as post- induction chemotherapy and filgrastim administration of timing (72hr and same day) were 30.94% and 15.28%. Conclusion: When medical oncologists and pharmacists worked together to establish criteria, our study made it possible to put into practice a system-wide pharmacist reference. Patients who got G- CSFs (Filgrastim) frequently started receiving treatment for reducing neutropenia, lessening its severity, and accelerating neutrophil recovery. Early initiation of filgrastim prophylaxis in patients at high risk of febrile neutropenia may help optimize chemotherapy delivery and improve patient outcomes. Further prospective studies are warranted to validate these findings and establish guidelines for the use of filgrastim in this patient population
- 1 January 2024
- Published by Cihan University of Erbil
- p. 505-509
Effect of Filgrastim in Febrile Neutropenia Patients Who Received Chemotherapy Regimens in The Community on Oncology Practice
—Background: Granulocyte colony-stimulating factors (G-CSFs) have been shown to help prevent febrile neutropenia in certain subgroups of cancer patients undergoing chemotherapy, but their role in treating febrile neutropenia is controversial. The purpose of our study was to evaluate—in a prospective multicenter randomized clinical trial—the efficacy of adding G-CSF to broad- spectrum antibiotic treatment of patients with solid tumors and high-risk febrile neutropenia. Patients and Methods: . This retrospective cohort study included seventy adult patients of both genders, aged 20 years and older, treated for cancer at Nanakali Hospital between October 2021 and January 2022. Data on filgrastim use and treatment outcomes were collected from electronic medical records. Results: Patients with 35 (50%) male and 35 (50%) female patients were assessed Based on observations from the administration series, (G-CSFs) use. Higher level acute myeloid leukemia (N=25) and lower one larynx carcinoma (N=1) were the most common malignancies, both of which were treated with (G-CSFs) as post- induction chemotherapy and filgrastim administration of timing (72hr and same day) were 30.94% and 15.28%. Conclusion: When medical oncologists and pharmacists worked together to establish criteria, our study made it possible to put into practice a system-wide pharmacist reference. Patients who got G- CSFs (Filgrastim) frequently started receiving treatment for reducing neutropenia, lessening its severity, and accelerating neutrophil recovery. Early initiation of filgrastim prophylaxis in patients at high risk of febrile neutropenia may help optimize chemotherapy delivery and improve patient outcomes. Further prospective studies are warranted to validate these findings and establish guidelines for the use of filgrastim in this patient population
- Open Access
- 20 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 11853
How Internet Websites Portray Herbal Vitality Products Containing Eurycoma longifolia Jack: An Evaluation of the Quality and Risks of Online Information
Background: Tongkat Ali (TA) or Eurycoma longifolia is a herbal medicine (HM) plant traditionally used to treat sexual dysfunction and enhance libido in men. Websites containing information about HM are abundant. However, studies have shown that in general the quality of websites containing information on HM is low. The present study aims to assess the quality and risks of websites containing information about TA supplements and to identify the health claims for TA. Methodology: A cross-sectional study to evaluate the quality and risks of websites discussing TA supplements was conducted. Online marketing websites, research articles, news articles, personal opinions, and those restricted by password were excluded. The quality and risks of websites were assessed using a modified DISCERN tool and a set of risk assessment criteria, respectively. The health claims for TA were identified and analyzed using content analysis. Results: Overall, 321 websites met the inclusion criteria and were further evaluated. The overall rating of the quality of the websites was low, with a mean score ± standard deviation of 1.07 ± 0.51. Most websites lacked information that there may be more than one possible treatment choice and did not discuss areas of uncertainty. However, 67.9% (218/321) of the websites received a risk score of zero. A minority of websites (5/321, 1.6%) discouraged the use of conventional medicines. The most common health claims for TA included in the websites related to the enhancement of testosterone level (121/321, 37.7%), treatment of malaria (112/321, 34.9%), and improvement in libido (108/321, 33.6%). Conclusions: Websites containing information about TA supplements generally have a low-quality rating based on a modified DISCERN tool despite having a low-risk score. Government agencies and healthcare professionals (HCPs) must be more proactive in the critique and dissemination of information relating to HM, and in ensuring the safe use of HM among the public and patients.
- 20 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 11853
Open AccessHow Internet Websites Portray Herbal Vitality Products Containing Eurycoma longifolia Jack: An Evaluation of the Quality and Risks of Online Information
Background: Tongkat Ali (TA) or Eurycoma longifolia is a herbal medicine (HM) plant traditionally used to treat sexual dysfunction and enhance libido in men. Websites containing information about HM are abundant. However, studies have shown that in general the quality of websites containing information on HM is low. The present study aims to assess the quality and risks of websites containing information about TA supplements and to identify the health claims for TA. Methodology: A cross-sectional study to evaluate the quality and risks of websites discussing TA supplements was conducted. Online marketing websites, research articles, news articles, personal opinions, and those restricted by password were excluded. The quality and risks of websites were assessed using a modified DISCERN tool and a set of risk assessment criteria, respectively. The health claims for TA were identified and analyzed using content analysis. Results: Overall, 321 websites met the inclusion criteria and were further evaluated. The overall rating of the quality of the websites was low, with a mean score ± standard deviation of 1.07 ± 0.51. Most websites lacked information that there may be more than one possible treatment choice and did not discuss areas of uncertainty. However, 67.9% (218/321) of the websites received a risk score of zero. A minority of websites (5/321, 1.6%) discouraged the use of conventional medicines. The most common health claims for TA included in the websites related to the enhancement of testosterone level (121/321, 37.7%), treatment of malaria (112/321, 34.9%), and improvement in libido (108/321, 33.6%). Conclusions: Websites containing information about TA supplements generally have a low-quality rating based on a modified DISCERN tool despite having a low-risk score. Government agencies and healthcare professionals (HCPs) must be more proactive in the critique and dissemination of information relating to HM, and in ensuring the safe use of HM among the public and patients.